158 related articles for article (PubMed ID: 26179198)
1. Demyelinating polyneuropathy after long-term treatment with infliximab.
Nakamura K; Hamaguchi T; Yamada M
Int J Rheum Dis; 2017 Nov; 20(11):1781-1782. PubMed ID: 26179198
[No Abstract] [Full Text] [Related]
2. Neurological complications of infliximab.
Jarand J; Zochodne DW; Martin LO; Voll C
J Rheumatol; 2006 May; 33(5):1018-20. PubMed ID: 16511935
[TBL] [Abstract][Full Text] [Related]
3. Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment.
Tektonidou MG; Serelis J; Skopouli FN
Clin Rheumatol; 2007 Feb; 26(2):258-60. PubMed ID: 16683176
[TBL] [Abstract][Full Text] [Related]
4. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
[TBL] [Abstract][Full Text] [Related]
5. New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients.
Tanno M; Nakamura I; Kobayashi S; Kurihara K; Ito K
Clin Rheumatol; 2006 Nov; 25(6):929-33. PubMed ID: 16328088
[TBL] [Abstract][Full Text] [Related]
6. Infliximab Therapy and the Central Nervous Demyelination in Patients with Kawasaki Disease.
Sagara Y; Muneuchi J; Shimabukuro W; Joo M; Yoshino M; Nakamura R; Yoneda T; Sugitani Y; Watanabe M; Mizushima A; Takahashi Y
Pediatr Infect Dis J; 2019 Aug; 38(8):e185-e187. PubMed ID: 31107420
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.
Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Hong SJ; Kim HA; Koh EM; Lee HS; Suh CH; Yoo DH; Bae SC
Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924
[TBL] [Abstract][Full Text] [Related]
8. Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha.
Hirotani M; Nakano H; Ura S; Yoshida K; Niino M; Yabe I; Sasaki H
Intern Med; 2009; 48(5):373-5. PubMed ID: 19252365
[TBL] [Abstract][Full Text] [Related]
9. Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists.
Alshekhlee A; Basiri K; Miles JD; Ahmad SA; Katirji B
Muscle Nerve; 2010 May; 41(5):723-7. PubMed ID: 20405504
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of 1 hour infliximab infusions.
van Vollenhoven RF; Gullström E; Klareskog L
Ann Rheum Dis; 2005 Apr; 64(4):654. PubMed ID: 15769930
[No Abstract] [Full Text] [Related]
11. [TNF inhibitors].
Kameda H
Nihon Rinsho; 2016 Jun; 74(6):957-62. PubMed ID: 27311185
[TBL] [Abstract][Full Text] [Related]
12. Peripheral neuropathy during infliximab therapy for rheumatoid arthritis.
El Aidli S; Gaïes E; Cherif F; Zaiem A; Daghfous R; Lakhal M
Presse Med; 2014 Sep; 43(9):1012-4. PubMed ID: 24742611
[No Abstract] [Full Text] [Related]
13. Haemophagocytic lymphohistiocytosis associated with leishmaniasis reactivation: a potential adverse event to anti-tumour necrosis factor-α therapy.
Bukan KB; Nardo-Marino A; Hagdrup C; Boennelycke M; Breinholdt MF; Schöllkopf C; Nielsen HV; El Fassi D
Scand J Rheumatol; 2019 Jul; 48(4):342-343. PubMed ID: 30526204
[No Abstract] [Full Text] [Related]
14. Unaffected reaction level in tuberculin skin test by long-term therapy with tumor necrosis factor inhibitors for rheumatoid arthritis.
Yamamoto S; Nagatani K; Sato T; Iwamoto M; Takatori S; Minota S
Int J Rheum Dis; 2017 May; 20(5):584-588. PubMed ID: 28524434
[TBL] [Abstract][Full Text] [Related]
15. Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody.
Mori S; Imamura F; Kiyofuji C; Sugimoto M
Mod Rheumatol; 2006; 16(4):251-5. PubMed ID: 16906378
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis of amyotrophic lateral sclerosis in a patient treated with TNFalpha blockers for ankylosing spondylitis: fortuitus association or new side effect of TNFalpha blockers?
Loustau V; Foltz V; Poulain C; Rozenberg S; Bruneteau G
Joint Bone Spine; 2009 Mar; 76(2):213-4. PubMed ID: 18955008
[No Abstract] [Full Text] [Related]
17. Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?
Conaghan PG; Quinn MA; O'Connor P; Wakefield RJ; Karim Z; Emery P
Arthritis Rheum; 2002 Jul; 46(7):1971-2; author reply 1973. PubMed ID: 12124886
[No Abstract] [Full Text] [Related]
18. Infusion reaction to infliximab in a patient with rheumatoid arthritis after discontinuation over 1 year and readministration.
Toki H; Momohara S; Tsukahara S; Ikari K
J Rheumatol; 2008 Sep; 35(9):1896-7; author reply 1897. PubMed ID: 18785300
[No Abstract] [Full Text] [Related]
19. Premedication prevents infusion reactions and improves retention rate during infliximab treatment.
Bartoli F; Bruni C; Cometi L; Blagojevic J; Fiori G; Tofani L; Galluccio F; Furst DE; Matucci Cerinic M
Clin Rheumatol; 2016 Nov; 35(11):2841-2845. PubMed ID: 27436188
[TBL] [Abstract][Full Text] [Related]
20. Multifocal Motor Neuropathy Associated With Infliximab: A Case Report and a Literature Review.
Bayrak AO; Ulusoy H; Bolat N; Doğan B; Ozbenli T
Neurologist; 2017 Jul; 22(4):144-146. PubMed ID: 28644258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
